The invention also concerns the resulting active principle and cosmetic compositions incorporating said active principle.
The active principle is incorporated into the micelles and, subsequently, the precipitation of the carrier polymer is triggered with the active principle.
Described is a pharmaceutical and/or cosmetic preparation for topical application, the preparation containing, in addition to at least one active principle, a carrier material designed to convey the active principle into the skin.
preparations with gradual release of the active principle
The protein active principle is not denatured.
The inventive laminates containing an active substance have a high content of active substances and effect a high active substance flux throughout the skin.
At least the first layer contains undissolved active substance in the form of active substance particles, said active substance being fentanyl or a fentanyl analogue.
If the water is charged with an active substance or, for example, the adsorption agent is mixed with an active substance, an aqueous aerosol charged with an active substance is formed.
Mesopram is used as an active substance.
The invention concerns a medicament for treating central and peripheral arterial occlusive vascular diseases, micro-angiopathies and/or acute and chronic micro-circulatory disturbances, the medicament containing magnesium ions as active substance.
More preferably the active ingredient comprises at least one suitable pharmaceutical active ingredient, cosmetic active ingredient, toiletries active ingredient and/or any compatible mixture thereof.
The form of administration consists of an inner section containing the active ingredient and surrounded by a coating, free of the active ingredient, in such a manner that the active ingredient is released rapidly.
The pellets can be obtained by spraying active-ingredient-containing granules with a solvent for the active ingredient or with an active-ingredient-containing liquid.
When Ca is used in the PAM delivery product, it is present in a 9:1 ratio to the PAM There are no fixing agents needed in the PAM delivery product; it is pure active ingredient.
As an active ingredient, any active ingredient used in general in the composition of tablets may be added.
The active pharmaceutical ingredient is preferably carbonyl iron.
The present invention relates to the active pharmaceutical ingredient dipyridamole.
An extended release composition for an analgesic active pharmaceutical ingredient which may be an opioid, preferably hydrocodone as the only active ingredient.
A tablet for the controlled release of an active pharmaceutical ingredient.
The present invention relates to an improved process for the preparation of the active pharmaceutical ingredient, vorinostat.
These micro-tablets are capable of releasing the API in more than 8 hours and are thus capable of providing a once daily formulation for the said API.
The tablet is formed by spray coating a support excipient with the API.
Hypersensitivity to the active substance, or to amoxapine.
Hypersensitivity to the active substance, or to amoxapine.
In another aspect of the present invention, the ODT contains a high load of at least one API.
The active is a hydrophobic active, typically a high-dose active.
The active kibbles can be mixed with non-active kibbles.
The active agent formulation includes an active agent and an aqueous liquid component.
The barrier is interposed between the active agent component and the adverse agent component.
A method of delivering a primary active agent and a secondary active agent to a locus.
The compositions combine an anti-infective and/or antimicrobial active agent in a carrier.
Also disclosed are compositions containing the treated castor oil and an active agent such as a pharmaceutical agent.
The composition includes an active agent or the active agent is added during administration of the composition.
An encapsulated ingredient is disclosed comprising an ingredient component and a coating component.
The continuous phase is then removed from the polymer/active agent solution, thereby forming a solid polymer/active agent matrix.
Said medicament or combination of medicaments contains at least one active agent and at least one antagonist of said active agent.
The composition comprises 2-methylisothiazoline-3-on as biocidal active ingredient and at least one other biocidal active ingredient.
This product is an intermediate product in the synthesis of cough-relieving dextromethorphanne and analgesic levorphanol.
The internal phase contains the active agent.
The vesicle can enclose an active ingredient.
Requêtes fréquentes français :1-200, -1k, -2k, -3k, -4k, -5k, -7k, -10k, -20k, -40k, -100k, -200k, -500k, -1000k,
Requêtes fréquentes anglais :1-200, -1k, -2k, -3k, -4k, -5k, -7k, -10k, -20k, -40k, -100k, -200k, -500k, -1000k,
Traduction Translation Traducción Übersetzung Tradução Traduzione Traducere Vertaling Tłumaczenie Mετάφραση Oversættelse Översättning Käännös Aistriúchán Traduzzjoni Prevajanje Vertimas Tõlge Preklad Fordítás Tulkojumi Превод Překlad Prijevod 翻訳 번역 翻译 Перевод